同源康醫藥-B(02410.HK)：TY-302、TY-2699a及TY-0540的I期臨牀試驗結果獲2025年歐洲腫瘤內科學會(ESMO)大會以壁報形式收錄
格隆匯7月24日丨同源康醫藥-B(02410.HK)公吿，公司自主研發的三款臨牀產品TY-302、TY-2699a及TY-0540的I期臨牀試驗結果，正式獲2025年歐洲腫瘤內科學會(ESMO)大會以壁報形式收錄。相關詳細數據將於會議期間展示，並同步發表於ESMO官方期刊《Annals of Oncology》。
TY-302是一種為治療乳腺癌及前列腺癌等晚期實體瘤而開發的強效、選擇性口服細胞週期蛋白依賴性激酶4/6("CDK4/6")抑制劑。TY-302以關鍵細胞週期調節因子CDK4/6為靶點，抑制視網膜母細胞瘤蛋白("Rb")的磷酸化，從而防止癌細胞增殖。TY-302通過氘代對全球最暢銷的CDK4/6抑制劑帕博西尼進行改良。臨牀前研究顯示其具有更低的胃腸道副作用和更可控的血液學毒性特徵。I期臨牀數據顯示，該藥物與託瑞米芬聯用治療HR+╱HER2－晚期乳腺癌末線患者時，展現出顯著療效和良好安全性。本次收錄數據來自I期多中心聯合用藥臨牀試驗(NCT04433494)，後續臨牀研究持續開展中。
TY-2699a是一種選擇性CDK7抑制劑，用於治療晚期╱轉移性實體瘤。臨牀前研究證實，該藥物可在正常細胞不敏感的劑量下精準抑制癌細胞生長。初步臨牀數據顯示，TY-2699a在同類劑量水平下兼具優異安全性和初步療效。本次收錄數據源自I期多中心單藥遞增臨牀試驗(NCT05866692)，目前針對三陰性乳腺癌(TNBC)的單藥擴展試驗正在進行。
TY-0540是一種選擇性CDK2抑制劑，擬用於治療乳腺癌、卵巢癌及前列腺癌等其他實體瘤。作為公司醫藥自主研發的CDK2/4抑制劑，TY-0540對CDK2/CycA2、CDK2/CycE1等核心靶點表現出強效抑制作用，同時對CDK4/CycD1、CDK6/CycD3等關聯靶點亦具備抑制活性。臨牀前和臨牀研究顯示，該藥物在乳腺癌(包括哌柏西利耐藥模型)、卵巢癌等多種實體瘤中均展現出顯著抑制效果及良好安全性。本次收錄數據來自I期多中心開放臨牀試驗(NCT06246071)，目前Ib/II期臨牀研究正在推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
